Latest James E. Muller Stories
BURLINGTON, Mass., Dec. 23, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center (MLSC) Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011. The Life Sciences Tax Incentive Program was established in 2008 as part of the...
BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the publication of a case report in Circulation describing the association of stent thrombosis with lipid core plaque as detected by its LipiScan(TM) Coronary Imaging System. The LipiScan is the first and only FDA-approved system to provide a Chemogram(TM) (map of lipid core plaque) within the imaged vessel via...
BURLINGTON, Mass., Dec. 3, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that James E. Muller, M.D., founder and chief executive officer, will be presenting at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference, to be held December 7-8, 2010, at the Nikko Hotel in San Francisco. The InfraReDx presentation is scheduled to take place on Tuesday, December 7...
BURLINGTON, Mass., Nov. 12, 2010 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the upcoming presentation of three LipiScan(TM)-related scientific abstracts at the American Heart Association Scientific Sessions 2010 (AHA 2010), being held Nov. 13-17, 2010 at McCormick Place in Chicago. The research being presented includes an oral abstract session focused on cost effectiveness and screening...
BURLINGTON, Mass., Oct. 12 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the completion of a $21 million equity financing. This round of investment attracted new institutions as well as existing investors, including Sanderling Ventures. Funds from the financing are being used to support the full commercial launch of the LipiScan(TM) IVUS Coronary Imaging System, the world's first and only...
BURLINGTON, Mass., Sept. 17 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that its new LipiScan(TM) IVUS Coronary Imaging System will be highlighted during the annual Transcatheter Cardiovascular Therapeutics meeting (TCT 2010). The novel device, which was recently cleared by the U.S. Food and Drug Administration (FDA), will be featured in scientific and clinical symposia, live case...
BURLINGTON, Mass., Sept. 1 /PRNewswire/ -- InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the LipiScan(TM) IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy to help cardiologists identify and...
BURLINGTON, Mass., June 16 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased tissues, today announced that its LipiScan(TM) Coronary Imaging System will be featured at the 13th Annual Live Symposium of Complex Coronary & Vascular Cases ("the CCC Symposium") being held at The Mount Sinai Medical Center of New York, from June 16-19, 2010. The CCC Symposium is a...
BURLINGTON, Mass., March 10 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's LipiScan(TM) Coronary Imaging System will be highlighted in multiple sessions during the 59th Annual Scientific Session of the American College of Cardiology (ACC). The meeting, named ACC.10 and i2 Summit, is being held from March...
BURLINGTON, Mass., Feb. 18 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's founder and chief executive officer, James E. Muller, M.D., will present and participate in a number of sessions and panel discussions during the annual Cardiovascular Research Technologies (CRT) 2010 meeting. CRT 2010, sponsored...
